What to know first
- USPSTF recommends an individual decision for men ages 55–69 after discussing benefits and harms.
- Routine PSA screening is not recommended for men 70 and older under current USPSTF guidance.
- A higher PSA is not the same as a cancer diagnosis.
Balance benefit and harm
Screening may prevent a small number of prostate cancer deaths and metastatic cancers, but it can also lead to false positives, biopsies, overdiagnosis, and treatment of cancers that would never have caused harm. Treatment can affect urinary, sexual, and bowel function.
Risk can differ with family history and ancestry. A clinician can help place personal risk beside the evidence rather than offering the test as automatic.
Questions for the visit
Ask what a result would change, how an elevated PSA would be evaluated, what active surveillance means, and how your other health conditions affect potential benefit. Clarify whether medicines, prostate enlargement, infection, or recent procedures could influence the test.
New urinary symptoms, blood in urine or semen, bone pain, or unexplained weight loss need clinical evaluation; screening guidance is not a symptom-management plan.
Sources and further reading
We prioritize authoritative public-health and government sources. Open each source to review the original guidance and latest updates.